Can You Justify Buying Corcept Stock Today?

For questions about this article or underlying research, email help@trefis.com.

Corcept Therapeutics (CORT) stock trades at 7.9 times its revenue over the past twelve months, compared with 3.3 times for the S&P 500. Anyone buying at that level is paying today for sales the drug maker has yet to generate. So how fast would Corcept have to grow just for the stock to hold its value?

How Fast Would Corcept Have To Grow?

At its current price, Corcept would have to grow its revenue about 11.9% a year for five years simply to maintain its present market value, leaving a buyer with no additional gain.

We base that growth rate on three assumptions. First, we assume Corcept’s multiple settles at a mature P/E of 22.8. We calculate that target by applying a 60% weight to the level of 18 we use for the pharmaceuticals and biotechnology group, and assigning the remainder to Corcept’s own average. Over the last twelve quarter-ends, that average stood at 62, which we cap at 30 under our methodology. Corcept currently trades at a P/E over the past twelve months roughly twice our assumed mature level. Furthermore, part of the profit driving that multiple came from non-operating sources. In fiscal Q4 2025, Corcept booked a $24.3 million profit on $4.49 million of operating income. Without that outside income, Corcept’s P/E would be even higher.

Corcept held a market value of $7.64 billion at the November 5 close. To support that valuation under our assumed mature P/E, the company would need to generate a yearly profit of $335 million. Earning that profit at a net margin of 19.8% requires revenue of $1.69 billion. We set that margin halfway between Corcept’s average of 17.1% and its peak of 22.6% over the last twelve quarter-ends. With revenue over the past twelve months at $964 million, Corcept would have to grow at that 11.9% annual pace to reach that mark over the five years we assume its P/E takes to come down.

Is Corcept’s Revenue Growing Faster Than That?

Yes. Corcept generated $340 million in revenue during fiscal Q3 2026, representing a 64% increase from a year earlier. Of that total, $91.4 million came from Lifyorli, a drug for platinum-resistant ovarian cancer launched in April. Korlym and its authorized generic brought in the rest.

During its November 3 call, management repeated a fiscal 2026 revenue guide of $1.1 billion to $1.2 billion, placing the midpoint 51% above fiscal 2025. If Corcept achieves that midpoint, the company would only need to grow about 8.4% a year after fiscal 2026 for its market value to hold. That required rate sits far below the pace guided for fiscal 2026 itself. Management also expects its current Cushing’s syndrome business to generate at least $2 billion a year by the end of this decade, which exceeds the revenue Corcept would require in the twelve months to fiscal Q3 2031.

Corcept Would Need Faster Growth Over Fewer Years

The required pace depends most on how many years we allow. If Corcept’s P/E dropped to the mature level in three years instead of five, the company would have to grow about 20.6% a year. If its net margin stayed at the 16.8% seen over the past twelve months, the required pace would be about 15.6% a year.

Corcept’s revenue has beaten the five-year pace in every twelve-month period ending in September since 2022. It cleared the mark by only about a point in 2022 and 2023, coming in at 12.7% and 13.2%. The company topped the three-year pace only in 2024 and 2026.

For today’s price to hold, Corcept has to keep growing for years after fiscal 2026. The company must grow faster if its net margin fails to rise above today’s level. Should its P/E fall to the assumed mature level sooner, Corcept would need to grow faster than it did in most of those prior periods, and the stock would be a riskier bet. Revenue growth in the fiscal Q4 2026 report, expected in February 2027, is the number to watch.

Does This Mean You Should Act On CORT?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.

Spot an error or want more like this? Tell us in 10 seconds.